SyntheticMR has appointed Lena Aredal to new CEO, with entry into office no later than December 15, 2025. Åredal, currently CEO of Perimed, has solid experience in medical technology and Life Science, including building sales organizations and raising capital. Johanna Norén will remain as acting CEO until Åredal takes office and then returns to the role of CFO. The board sees Åredal's commercial drive as crucial to the company's growth.
Lena Åredal appointed new CEO of SyntheticMR
Notes
iZafe takes the next step in the Nordics – begins Finnish partnership for Dosell
Senzime's partner receives FDA approval for TetraGraph module
Ellen sells the business for SEK 13,3 million
Oncopeptides increases sales in the second quarter
Alvotech acquires Ivers-Lee Group in Switzerland
NEWSLETTER
NEWS
Merck gears up in lung diseases with giant acquisition
AstraZeneca strengthens gene therapy portfolio with deals worth up to $825 million
AlzeCure Pharma: “We have good momentum”
Upcoming events!
Investing in Life Science
Discover unparalleled opportunities, set in the vibrant heart of Stockholm. This premier event unites forward-thinking investors and business leaders to...
Life Science Summit
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account
Chronicles
The EU's new life science strategy – a step in the right direction or just fluff?
Early signs of spring in an otherwise frosty biotech landscape
